For pharmaceutical and biotech companies or research laboratories looking for high level partners devoted to healthcare and biotech, ATLANPOLE Biotherapies is a cluster that draws together a community of innovative companies, fundamental & clinical research organizations and higher education institutions, all located in Western France. To ensure the development of biotherapies at an International level, the cluster has developed a broad network of global partnerships, already leading to effective cooperation between cluster members.
ATLANPOLE Biotherapies gives you access to extended skills, from biodiagnostic to biomedicine. Its stakeholders offer comprehensive and competitive solutions along the entire biotherapeutic value chain, from discovery to patient, with areas of excellence such as biomanufacturing, vector development or clinical evaluation.
Atlanpole Biotherapies cluster focuses on 3 major therapeutic areas:
Atlanpole Biotherapies cluster benefits from a strong history in the field of immunology with first applications designed for the transplantation and oncology therapeutic armamentarium development.
This excellence lead to many company creations directly involved in, or related to, the business of antibodies or tumor vaccines. More recently the performance of the immunology community was rewarded by the French government granting the “IGO Labex” (“Immuno Graft Oncology laboratory of excellence) and of the “IHU CESTI project” (European Clinical Center for Transplantation Sciences). These two projects aim not only at improving recent developments in diagnostics and therapies in transplantation or oncology but also at developing next generation tools. Thus alternatives to organ grafts are developed and tested with cell and gene therapies techniques as well as combined biologics approaches.
Among audacious strategies developed in these projects, we can also mention the use of innovative radioisotopes that can be produced in the Arronax High-Energy cyclotron. As our community is experienced in various biotherapy developments and manufacturing techniques, it has also set up a unique biomanufacturing education tool, “Biopractis Training Center”. It offers a GMP-like facility to train employees and students with pilot-scale industrial equipments. It also provides a program of workshops that are opportunities for high level executives to share their ideas about very specific technical issues they
want to solve.
2. Radiopharmaceuticals: “Isotop 4 life“
Intensive research in nuclear imaging, targeted radionuclide therapy with radio-immunotherapy (RIT) and radiobiology is being performed around the high-energy and highintensity cyclotron Arronax in Nantes. The main developments underway
in nuclear imaging consist in innovative technologies for oncology, neurology and cardiac applications as well as improved measurement of radiopharmaceuticals biodistribution. RIT has shown promising results in clinical trials against cancers resistant to other treatments. RIT for cancers with poor prognosis is a focus of our cluster with special emphasis on a proprietary radio-labeled monoclonal antibody with completed Phase II clinical development to fight residual prostate
cancer. Finally Atlanpole Biotherapies provides a comprehensive value chain for assessing your lead compounds
namely trough a fully operating and open access “Whole Body Imaging HUB”. The unique, 70 MeV and 750A cyclotron Arronax, allows production of new radionucleides such as Gallium-68, Iodine 124, Copper-64, Rubidium-82, Copper-67, and alpha particles like Astatine-211.
3. Regenerative medicine
Our large community of regenerative medicine stakeholders is boosting this topic by the cross fertilization of several
technologies such as biomaterials and cell and gene therapies. This strategy is supported by strong medical expertises in oncology, dermatology, cardiology, orthopedia and rare diseases and by specialized core facilities for immunomonitoring,
biomanufacturing, developing and supplying a wide range of synthetic or viral carriers and by a strong knowhow in experimental preclinical surgery and in safety tests development. Our community is also committed in various ambitious projects at the regional, national or European scales:
• It is involved in a national project aiming at structuring the large scale manufacturing of cell based therapeutic products (C4C) or leading gene therapy manufacturing initiative (PGT industrial demonstrator facility).
• Several European and international collaborations are already successful. The European R&D projects GAMBA (Gene Activated Matrices for Bone and Cartilage Regeneration in Arthritis) and REBORNE (Regenerating Bone Defects using
New biomedical Engineering approaches) illustrate the strengths in the field of orthopedia.
These successes also rely on a strong european networking culture of our players.For example they are contributors in interclustering projects such as TERM (Tissue Engineering and Regenerative Medicine) and BIOMAT’IN (Biomaterials Innovation Netwok). They also lead a Doctorate Erasmus Mundus Program (Nanofar).
Thus Atlanpole Biotherapies Regenerative Medicine assets are an attractive network to join for top level students, clinicians and scientists or to set up new businesses.
The cluster confirms the Pays de la Loire region’s dynamism and exponential growth in the life & health sciences.To further extend its access to excellent skills and competencies, ATLANPOLE Biotherapies is already engaged in a number of strategic partnerships, leading to practical cooperations with bioclusters in Berlin, Milano, the Netherlands, the United Kingdom, Belgium, Tartu, Madrid, Göteborg, Uppsala…
Through one-to one interactions or within more global frameworks such as the European Commission’s, partners
already engaged transnational technology transfers, and provided business opportunities for their stakeholders.
The cluster itself is also coordinating a european network, and setting up a new one.
Your potential partners
ATLANPOLE Biotherapies Cluster is one of the most growing innovation environment, with a fast increase of researchers number over the past decade leading to a new University Hospital, the development of 4 new biotech start ups every year,
the creation of 2 biotech incubator buildings opening in 2009 and 2012
• 73 Companies
• 51 Research Units
• 42 core facilities providing high-tech services to industry & academia
• 1200 specialist researchers
• 5 universities (Nantes, Angers, Rennes, Tours and Poitiers)
• 2 university medical centers (Nantes, Angers)
• 1 veterinary school - ONIRIS
• 1 International Management school - Audencia
• 5 institutes combining fundamental & clinical research in Transplantation, Cancer, Cardiovascular, Pulmonary and Gastrointestinal diseases.
The biotherapeutic value chain:
• Basic research
• Drug discovery and optimization
• Preclinical development
• Diagnosis & therapeutic innovations
• Biomanufacturing / bioprocessing
• Clinical research & evaluation
Learn more about our international networks on:
• Regenerative Medicine: www.termproject.eu
• Biomaterials: www.biomatin.eu
• Radiopharmaceuticals: www.isotop4life.com